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Abstract
Apical Membrane Antigen 1 (AMA1) is a leading malaria vaccine candidate and a target of naturally-acquired human
immunity. Plasmodium falciparum AMA1 is polymorphic and in vaccine trials it induces strain-specific protection. This
antigenic diversity is a major roadblock to development of AMA1 as a malaria vaccine and understanding how to overcome
it is essential. To assess how AMA1 antigenic diversity limits cross-strain growth inhibition, we assembled a panel of 18
different P. falciparum isolates which are broadly representative of global AMA1 sequence diversity. Antibodies raised
against four well studied AMA1 alleles (W2Mef, 3D7, HB3 and FVO) were tested for growth inhibition of the 18 different P.
falciparum isolates in growth inhibition assays (GIA). All antibodies demonstrated substantial cross-inhibitory activity against
different isolates and a mixture of the four different AMA1 antibodies inhibited all 18 isolates tested, suggesting significant
antigenic overlap between AMA1 alleles and limited antigenic diversity of AMA1. Cross-strain inhibition by antibodies was
only moderately and inconsistently correlated with the level of sequence diversity between AMA1 alleles, suggesting that
sequence differences are not a strong predictor of antigenic differences or the cross-inhibitory activity of anti-allele
antibodies. The importance of the highly polymorphic C1-L region for inhibitory antibodies and potential vaccine escape
was assessed by generating novel transgenic P. falciparum lines for testing in GIA. While the polymorphic C1-L epitope was
identified as a significant target of some growth-inhibitory antibodies, these antibodies only constituted a minor proportion
of the total inhibitory antibody repertoire, suggesting that the antigenic diversity of inhibitory epitopes is limited. Our
findings support the concept that a multi-allele AMA1 vaccine would give broad coverage against the diversity of AMA1
alleles and establish new tools to define polymorphisms important for vaccine escape.
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Introduction
There is strong need for vaccines against malaria to combat the
global burden of disease, particularly in light of increasing drug
resistance [1] and the declining efficacy of vector control
interventions [2]. Apical Membrane Antigen 1 (AMA1) is a leading
vaccine candidate that is expressed by merozoites of Plasmodium
falciparum [3,4]. AMA1 is essential for blood-stage replication [5]
and antibodies to AMA1 inhibit erythrocyte invasion [6,7] making
AMA1 an attractive candidate on biological grounds. AMA1
vaccines have demonstrated protective efficacy in rodent and
simian models, and evidence suggests that AMA1 is an important
target of naturally-acquired protective antibodies in humans [6–
10]. Antigenic diversity in AMA1 can mediate immune escape and
immunisation with AMA1 in animal models is typically protective
against homologous parasite challenge with reduced protection
against heterologous strains [11–14]. The capacity of AMA1 to
elicit protective immunity in humans was recently demonstrated
by a phase 2b vaccine trial of 1–6 year old children in Mali [15].
This trial, using a vaccine based on a single AMA1 allele, reported
64% protective efficacy against malaria episodes caused by
vaccine-like alleles, but no significant efficacy against episodes
due to other alleles. These findings demonstrate the potential of
AMA1-based malaria vaccines, but highlight the need for
strategies to overcome antigenic diversity and prevent vaccine
escape.
Currently, there is a limited understanding of antigenic diversity
of AMA1 and the requirements of AMA1 vaccines to give broad
population coverage. Approximately 10% of the amino acid
residues in AMA1 are polymorphic [16] and over 200 unique
haplotypes of AMA1 have been identified [17–18]. Despite this
diversity, recent sequence-based analyses suggests that sequences
may be grouped into as few as six clusters of related sequences
[18], although others suggest the number might be much larger
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[17] [19]. It is unclear how sequence polymorphisms and
sequence-based groupings relate to antigenic diversity and escape
from inhibitory antibodies. Studies of the antigenic diversity of
inhibitory epitopes have generally been limited to testing small
numbers of Plasmodium falciparum laboratory strains and provide
limited insight into the number and type of AMA1 alleles required
for an effective vaccine.
Clusters of polymorphisms that might contribute to antibody
escape have been identified on all three domains of AMA1 [20],
although domain 1 appears to be the major target of inhibitory
antibodies [21]. One cluster, known as C1-L, spans amino acids
196 to 207 of domain 1. The invasion-inhibitory monoclonal
antibody 1F9 binds this region, [22] and studies using recombi-
nant AMA1 proteins suggest this region is an important target of
strain-specific inhibitory antibodies. C1-L contains among the
most polymorphic residues of AMA1, including the heptamorphic
position 197. Longitudinal studies have associated polymorphisms
in C1-L with the development of clinical malaria, suggesting it is
a target of naturally acquired strain-specific AMA1 immunity [17].
In this study, we aimed to address these gaps in our knowledge
and advance the development of a broadly effective AMA1
vaccine. We compiled a diverse array of P. falciparum isolates to i)
measure the cross-inhibitory capacity of antibodies to different
AMA1 alleles generated by immunisation, ii) understand antigenic
diversity of inhibitory epitopes, iii) assess relationships between
sequence polymorphisms and immune escape, and iv) investigate
whether a multi-allele vaccine may be an effective and feasible
strategy to overcome antigenic diversity. Our studies focussed on
the growth-inhibitory activity of AMA1 antibodies because this is
thought to be the major mechanism of action [7]. Furthermore, we
developed a novel approach using transgenic P. falciparum with
defined mutations in AMA1 sequences to identify key polymorph-
isms, or polymorphic regions, responsible for escape from growth-
inhibitory antibodies. Using this approach, we quantified the
importance of residues in the C1-L for antibody escape.
Methods
Expression of Recombinant AMA1
The DNA sequences encoding W2Mef, 3D7, HB3 and FVO
ama1 alleles were codon optimised for expression in E.coli
(Genscript). The DNA sequence encoding amino acids 25 to 546
of the codon optimised ectodomain was PCR amplified using the
oligonucleotide primer sets A-D (Table 1) and ligated into the
66His expression vector pProEX HTb (Invitrogen) using Bam H1
and Xho 1 restriction sites. Plasmids were transfected into BL21
E.coli. Recombinant AMA1 expression, purification and refolding
was performed as previously described [6]. In brief, all proteins
were expressed as insoluble inclusion bodies in E. coli and then
solubilised in 6M Guanidine-HCL, which completely denatures
the recombinant proteins. After purification on nickel resin,
AMA1 protein was refolded with reduced and oxidized glutathi-
one redox pairs. Refolded AMA1 was further purified by anion-
exchange chromatography, followed by reverse phase high-
performance liquid chromatography. Refolded AMA1 was iden-
tified by a shift in the monomer peak on reverse phase HPLC and
a migration shift on SDS-PAGE when compared to a reduced and
alkylated sample of the refolded AMA1 preparation.
Immunisation of Rabbits and Generation of Antibodies
New Zealand White rabbits were immunised with 50 mg of
recombinant AMA1 emulsified in Freunds adjuvant. Rabbits were
injected intramuscularly three times over 4 week intervals using
standard procedures. Ethics clearance for rabbit immunisations
performed in this study was obtained from the Animal Ethics
Committee of the Walter and Eliza Hall Institute, Australia. Sera
was heat inactivated and screened for growth inhibition by GIA.
Sera generating the highest level of growth inhibition against
homologous isolates were selected for use in cross-strain GIAs
(anti-W2Mef #1, anti-3D7#1, anti-HB3#1 and anti-FVO#1).
Anti-3D7, anti-HB3 and anti-FVO AMA1 antibodies were
adjusted to 20 mg/ml of total IgG after purification on protein-
G sepharose. Anti-W2Mef #1and anti-FVO#2 rabbit antisera
were generated as previously described and tested as whole serum
in GIAs [6]. A pool of anti-W2Mef #1, anti-3D7#1, anti-HB3#1
and anti-FVO#1 antibodies was generated by combining equal
volumes of each of the four antibodies.
Parasite Culture and Genotyping
P. falciparum asexual stage parasites were maintained in culture
in human erythrocytes (blood group type O+) at a hematocrit of
4% in RPMI-HEPES supplemented with 0.25% (w/v) Albu-
maxTM (Invitrogen) and 5% (v/v) heat inactivated human serum
[23]. The origins of P. falciparum isolates used in this study are listed
in Table 2. [24–35] Isolates XHA-A, XHA-D, and BFD06 are
described for the first time in this study. Isolates XHA-A and
XHA-D were derived from the peripheral blood of two different
children in PNG (Madang Province, year 2004) [36] [10] and
adapted to in vitro culture over several weeks. BFD06 was isolated
in 2006 from an adult with acute malaria who returned from
travelling in Burkina Faso. The recovered parasites were re-
strictively diluted to isolate pure strains with isolate ‘‘D’’
perpetuated in culture. Genomic DNA was prepared from each
isolate, the sequence encoding the AMA1 ectodomain (aa 25–546)
was amplified by PCR and directly DNA sequenced using
oligonucleotide set G (Table 1).
P. falciparum Growth Inhibition Assays
P. falciparum growth inhibition assays (GIA) were performed as
described [37–40] with the following modifications: Synchronised
early trophozoite stage parasites were adjusted to 0.1% para-
sitemia and 2% hematocrit. Five ml of stock antibody or peptide
was added to 45 ml of infected red blood cells and mixed to
generate a final culture volume of 50 ml. Parasites were allowed to
develop through two cycles of erythrocyte invasion for 72 hours at
37uC. Early trophozoite stage parasites formed after the second
round of invasion were fixed for 1 hour at room temperature by
the addition of Glutaraldehyde (ProSciTech) to a final concentra-
tion of 0.25% (v/v). After fixation, parasites were washed in
HTPBS, stained with 106 SYBR green dye (Invitrogen) and
56105 red blood cells counted per well using a BD FACSCantoII
flow-cytometer. FACS counts were analysed using FlowJoTM(Ver
6.4.7) software (Treestar). Percent growth inhibition= (12[par-
asitemia in test well/mean parasitemia in pre-immunization rabbit
controls wells])6100. All GIAs were run in a 96-well plate format,
with each antibody or peptide tested in triplicate wells. Parasite
growth inhibition is represented as the combined mean of two
separate triplicate well assays set up on different days. Growth
inhibition by rabbit antibodies is expressed relative to non-
immunized control rabbits; there was no significant inhibition of
growth by IgG or whole serum from non-immunized control
rabbits. Purified antibodies were tested at a final concentration of
2 mg/ml total IgG; normal physiologic concentration of total IgG
is 10–15 mg/ml. Since it is not known how the levels of inhibition
in GIAs in vitro relate to the inhibitory or protective activity of
antibodies in vivo, the levels of inhibition by individual antibodies
and antibody pools tested in GIAs should be regarded as relative
inhibition, rather than absolute levels of inhibition, allowing
Multi-Allele AMA1 Vaccine for Malaria
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comparisons of the inhibitory activity between antibodies and
isolates. For analysis of the relationship between antibody
inhibition and polymorphisms in AMA1, results were standardized
such that the level of inhibition of the homologous isolate by anti-
allele antibodies was designated as 100% (E.g. Inhibition of 3D7
parasites by anti-3D7 antibodies was designated as 100%; no
inhibition was 0%). This was done to facilitate comparisons of the
inhibitory effects of different antibodies against the panel of
different isolates; the standardisation did not affect the correlation
coefficients or p values.
Generation of Transgenic P. falciparum
Transfection plasmids were assembled in pCC1 [41]. This
vector contains a hDHFR cassette driven by the Calmodulin
promoter. Expression of hDHFR mediates resistance to drug
WR99210 and enables positive selection of transfected parasites.
pCC1 also contains a ganciclovir resistance CD cassette which was
removed and replaced by an ama1 allelic exchange cassette
consisting of a W2Mef AMA1 targeting domain, the W2Mef
AMA1 promoter and an E.coli codon-optimised form of the new
AMA1 allele to be introduced. The W2Mef AMA1 targeting
domain was amplified by PCR using the oligonucleotide primer
set E (Table 1) and inserted into pCC1 using Spe1 and Xho1
restriction sites. This 917bp PCR product consists of the 59
domain of W2Mef AMA1 with a stop codon engineered at its 39
end. The 1429 bp W2Mef AMA1 promoter was PCR-amplified
using the oligonucleotide primer set F (Table 1) and inserted into
pCC1 using Xho1 and Kpn1 restriction sites to create the plasmid
Table 1. Oligonucleotides used for amplification of ama1 gene sequences.
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pCC1AMA1TP.1. Codon-optimised W2Mef, 3D7 and FVO
AMA1 alleles were synthesized with a 30 bp 59 UTR tag ahead
of the ATG start codon, in order to maintain the W2Mef AMA1
kozac consensus sequence upon integration. The 3F3 and F3F
hybrid C1-L alleles were constructed by Spliced Overlapping End
(SOE) PCR, using codon-optimised 3D7 or FVO AMA1 DNA as
templates and oligonucleotide sets H, I, J and K respectively
(Table 1). W2Mef hybrid alleles containing the C1-L sequence of
3D7, HB3, FVO, XIE, 2006 and Plasmodium reichenowi C1-L
(aa196–206) were constructed by SOE PCR using a codon-
optimised W2Mef AMA1 template, flanking oligonucleotide set L
and internal oligonucleotide sets M to R respectively (Table 1). All
AMA1 alleles were inserted into pCC1TP.1 using Kpn 1 and Pst 1
restriction sites. 3D7 and W2Mef parental parasites were
transfected using standard protocols [42]. Transfected parasites
were recovered after positive selection with WR99210 and
underwent Southern blot analysis to confirm AMA1 allelic
replacement had occurred. Southern blots were performed using
the DIG system (Roche) and genomic DNA extracted with the
Dneasy Tissue Kit (Qiagen). The DNA probe used for Southern
Blots was amplified from W2Mef genomic DNA using primer set
E (Table 1). Parasite populations confirmed to have plasmid
integration into the AMA1 target were cloned by limiting dilution,
and positive populations confirmed by Southern Blot.
SDS-PAGE (Polyacrylamide Gel Electrophoresis) and
Immunoblot Analysis
SDS-PAGE and Immunoblot analysis of parasite proteins was
performed as previously described [41]. Synchronised schizont-
stage parasite cultures were saponin-lysed, washed in phosphate
buffered saline (PBS) and resuspended in non-reducing SDS
sample buffer (Invitrogen). Samples were sonicated and heated to
100uC for 5 minutes prior to SDS-PAGE. Proteins were separated
on 3–8% Tris-Acetate gels (Invitrogen) and transferred onto
nitrocellulose using the iBlot system (Invitrogen) according to
standard protocols. Blots were probed with the relevant anti-
AMA1 rabbit antiserum (1:2000). Blots were also probed with
a mouse monoclonal antibody generated against the P. falciparum
HSP-70 protein (1:2000) as a loading control. Horseradish
peroxidase-coupled (HRP) goat anti-rabbit Ig (1:2000) or sheep
anti-mouse Ig (1:2000) Millipore) were used as secondary
antibodies.
Phylogenetic and Statistical Analysis
Amino acid sequence alignments and relative amino acid
identity scores were performed using Genious 5.5.6. software
(Biomatters). Phylogenetic trees were generated using ClustalW.
Statistical analysis was performed using Prism 5 (Graphpad
Software). Correlations between growth inhibition and sequence
identity scores were calculated by linear regression. Paired two-
tailed t-tests were used for comparisons between the level of
inhibitory activity between antibodies or between different isolates.
Results
Cross-inhibitory Activity of Antibodies to Different AMA1
Alleles
To understand the antigenic diversity of inhibitory epitopes of
AMA1 and the cross-inhibitory activity of antibodies, we
generated a panel of 18 different P. falciparum isolates that would
broadly represent AMA1 global diversity (Table 2). Isolates
originated from diverse geographical locations, including Africa,
South East Asia, Central and South America and Oceania. AMA1
sequences were determined and all isolates expressed distinct
AMA1 alleles except HCS-E5 and CSL-2, which have identical
sequences. AMA1 sequences of the isolates were compared to 250
different AMA1 alleles retrieved from the public database (using
an NCBI blast search). Analysis showed that the 17 distinct AMA1
alleles were spread throughout a phylogenetic tree (Figure 1A),
suggesting they are broadly representative of global AMA1
diversity. Additionally, at least one isolate was included from each
of the six haplotype clusters described by Duan et. al. 2008 [18].
The four alleles used for antibody generation were selected on the
basis that i) they broadly represent global AMA1 diversity based
on phyologenetic analysis (Figure 1), ii) they have a varied
distribution of polymorphic sites, iii) there is a high level of
sequence diversity between the alleles and iv) an isolate
corresponding to each allele could be cultured in vitro.
To assess AMA1 diversity within the 17 unique sequences of our
18 isolates, we constructed phylogenetic trees based on either the
ectodomain (Figure 1B) or C1-L (Figure 1C). The allelic identity of
ectodomain sequences ranged from 100% to 94.5%. Across the
521 aa ectodomain, 61 residues were polymorphic. The vast
majority of residues were divalent (52), with amino-acid positions
173, 188, 231, 244 and 504 being trivalent, position 200
quadravalent and position 197 pentavalent. There were nine
unique C1-L sequences identified. This diversity is similar to
a recent study in Mali which examined 247 AMA1 haplotypes and
identified 62 polymorphic residues, of which 46 were divalent [17].
This further indicates that our panel of 18 isolates broadly
represents global AMA1 diversity.
Each of the anti-AMA1 antibodies showed a unique pattern of
inhibitory activity against the panel of 18 isolates (Figure 2A). The
median level of growth inhibition for all isolates was similar for
each of the four anti-AMA1 antibodies (P,0.05), ranging from 42
to 52% (Figure 2B). The maximum level of inhibition achieved by
each of the four antibodies ranged between 75 and 95%, while the
minimal levels of inhibition ranged between 0 and 17%
Table 2. P. falciparum isolates used in this study.
Isolate Origin Reference
W2Mef SE Asia [24]











E8B Unknown (derived from IT4) [33]
HCS-E5 Thailand [30]
K1 Thailand [34]




BFD06 Burkina Faso Unpublished
doi:10.1371/journal.pone.0051023.t002
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(Figure 2B). The highest level of inhibition for anti-W2Mef and
anti-3D7 antibodies was seen against the corresponding parental
isolates. This was not observed for anti-HB3 and anti-FVO
antibodies, which showed maximum inhibition against BFD06,
a recent African isolate. Several isolates showed low inhibition
(#25%) by individual antibodies, suggesting that they may be
candidates for antibody, or vaccine, escape. Of note however, all
isolates were inhibited by $ 25% by at least one of the 4
antibodies tested. A pool of the four anti-allele antibodies was
prepared and tested against all isolates to evaluate the potential for
a multi-allele vaccine to give broad inhibitory activity against
different isolates. All isolates were substantially inhibited by the
antibody pool (Figure 2A). The pool increased the median
inhibition across all isolates to 56%, higher than the median
inhibition of individual anti-allele antibodies, and no isolate was
inhibited by less than 37% (Figure 2B). These findings suggest that
antigenic diversity of AMA1 is limited and there is substantial
antigenic overlap between different AMA1 alleles. Including four
different alleles in a vaccine may be sufficient to overcome AMA1
diversity.
AMA1 Sequence Diversity and Allele-specific Growth
Inhibition
We investigated relationships between polymorphisms in
AMA1 and levels of growth-inhibitory activity of the different
antibodies. AMA1 sequences were aligned and their sequence
identity to either W2Mef, 3D7, HB3 or FVO AMA1 was
calculated. This was performed for the whole ectodomain, and
each of domains 1, 2, and 3 (Figure 2C) and the C1-L
polymorphic region. Sequence identity scores were plotted
against relative growth inhibition values for each antibody
(Figure 3). The level of inhibitory activity by antibodies was not
strongly or consistently related to the extent of polymorphism
when assessing the entire ectodomain, specific domains or C1-L
region. Correlations between sequence identity and inhibition
also varied between anti-allele antibodies. Significant correla-
tions, of moderate strength, were seen for the ectodomain and
domains 1 for anti-W2Mef and anti-3D7 antibodies, but not for
anti-HB3 or anti-FVO. For the C1-L sequence analysis,
significant correlations were seen for anti-W2Mef and anti-
FVO antibodies, but not antibodies to 3D7 and HB3 alleles.
This suggests that the activities of each of the allelic antibodies
are influenced differently by polymorphisms across the ectodo-
main of AMA1. For example, anti-W2Mef and anti-FVO
inhibitory antibodies may be more influenced by changes in the
C1-L region, whereas anti-3D7 and anti-HB3 inhibitory appear
less influenced by this region. However, the overall weak-to-
moderate relationships between inhibition and sequence identity
highlight the limitations of using sequence analysis, on its own,
to define or predict antigenic diversity of inhibitory epitopes.
Figure 1. Phylogenetic analysis of AMA1 sequences. A. Phylogenetic tree of the AMA1 alleles expressed by 18 different isolates examined in
this study in relation to 250 other AMA1 alleles obtained from the public database. Analysis was based on the ectodomain sequence. B. Phylogenetic
tree of the AMA1 alleles expressed by the 18 different isolates used in this study, based on the AMA1 ectodomain sequence (amino acids 25–456).
The AMA1 sequences of HCS-E5 and CSL-2 were found to be identical. C. Phylogenetic tree of the AMA1 alleles expressed by isolates used in this
study, based on the C1-L sequence of AMA1 (amino acids 196–207). Translated ectodomain and C1-L protein sequences were aligned and
phylogenetic trees constructed using ClustalW2.
doi:10.1371/journal.pone.0051023.g001
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Evaluating the Importance of C1-L Residues for Antibody
Escape with the 3D7 Allele
To dissect the importance of C1-L polymorphisms for escape
from growth-inhibitory antibodies, we took a novel approach by
generating transgenic parasite lines expressing hybrid AMA1
alleles in which the C1-L region was modified. As controls, we
generated W2Mef parasites in which the endogenous AMA1 was
replaced with the codon-optimised W2Mef, 3D7 or FVO alleles.
Genotypes and phenotypes of transgenic parasites were confirmed
by southern blots and Western blots (Figure 4). In GIAs, wild type
and transgenic parasites expressing the same AMA1 allele were
inhibited at the same level by their corresponding antibodies
(Figure 4). In our first model we constructed plasmids containing
the 3D7 allele of AMA1 with the C1-L sequence from FVO
(named 3F3), or FVO-AMA1 with the C1-L sequence from 3D7
(named F3F). The C1-L region differs by 5 amino acids between
3D7 and FVO at residues 196, 197, 200, 204 and 206 (Figure 5A).
Plasmids were transfected into W2Mef parental parasites; howev-
er, only the 3F3-ama1 gene was successfully integrated into the
AMA1 locus (Figure 5B). A second round of F3F transfection was
again unsuccessful (data not shown), suggesting that the F3F-
AMA1 hybrid allele may not be functional. W2-3F3 parasites
completely escaped inhibition by monoclonal antibody 1F9,
confirming the loss of the 3D7 C1-L epitope that it binds. On
the other hand, R1 peptide inhibits invasion by binding to 3D7-
AMA1 independently of the C1-L [43]. W2-3F3 parasites were
strongly inhibited by R1, confirming the correct expression of 3F3-
AMA1 (Figure 5C). There was minimal inhibition by anti-W2Mef,
consistent with the replacement of the W2Mef allele with the 3F3-
hybrid allele.
We looked for differential inhibition of the W2-3F3 hybrid
compared toW2-3D7 and W2-FVO transgenic parasites in GIAs.
For anti-3D7 antibodies, there was no significant difference in
inhibition between the W2-3D7 and W2-3F3 transgenic lines
(Figure 5D). With anti-FVO antibodies, W2-3F3 parasites showed
a slight increase in growth inhibition, compared to that seen for
W2-3D7 parasites (FVO #1 P= 0.007, FVO #2 P=0.024).
Given the minimal effect on antibody inhibition of changes in the
C1-L region of 3D7-AMA1, mutations in this region were not
explored further.
C1-L Residues and Vaccine Escape with the W2mef Allele
To further assess the importance of C1-L residues, we used
a second transgenic model based on W2Mef-AMA1 allele. The
significance of C1-L in the W2Mef allele has not been reported,
but our preliminary analyses suggested that C1-L polymorphisms
Figure 2. Cross-strain growth inhibition by antibodies to different AMA1 alleles. A. The growth-inhibitory activity of polyclonal rabbit
antibodies raised against W2Mef, 3D7, HB3 and FVO AMA1 alleles. Anti-W2Mef whole serum was tested at a dilution of 1:10, and anti-3D7, anti-HB3
and anti-FVO rabbit purified IgG was tested a final concentration of 2 mg/ml IgG. Columns represent the mean parasite growth inhibition achieved in
two separate assays tested in triplicate wells. The 4-way pool contains 25% (v/v) of each antibody and was tested at a final dilution of 1:10. B
Summary of cross-strain growth-inhibitory activity of antibodies against all isolates. Results show the median (horizontal line) level of inhibitory
activity against the 18 isolates tested, and the interquartile range (box) and range (whiskers) of inhibitory activity. C Schematic representation of
PfAMA1. The positions of amino acids (aa) that define Domain I (D1), Domain II (DII) and Domain III (DIII) of the PfAMA1 ectodomain are shown. The
extracellular ectodomain is composed of aa 25 to 546 and excludes the signal sequence (SS), transmembrane domain (TM) and intracellular
cytoplasmic tail (CT) regions. Not to scale.
doi:10.1371/journal.pone.0051023.g002
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may be important. We constructed plasmids containing W2Mef
AMA1 with the C1-L from 3D7, HB3, FVO, XIE, or Pf2006
alleles, or from the related species, P. reichenowi (Pr), which
represented different levels of polymorphism naturally present in
populations (Figure 6A). Testing the impact of different modifica-
tions on growth inhibition might allow specific residues that are
important for vaccine escape to be identified. All plasmids were
transfected into W2Mef parental parasites (Figure 6B, 6C).
W2Mef hybrid ama1 genes containing the C1-L sequence of
HB3, XIE, Pf2006 or Pr were successfully integrated, whereas the
hybrids containing 3D7 or FVO C1-L sequences did not integrate
after the first or subsequent transfections. Parasites expressing the
HB3 or Pf2006 C1-L sequence were inhibited substantially less
than W2Mef (38% lower; p,0.001), whereas parasites expressing
the XIE or Pr C1-L did not escape inhibitory activity, and were
inhibited by 10% more than W2Mef (P,0.001, Figure 6D). This
suggests that specific polymorphisms in the C1-L have a major
influence on antibody escape for W2Mef. Both the HB3 and
Pf2006 alleles differ from W2Mef at residue 197, whereas XIE and
Pr do not. The latter two isolates have polymorphisms at residues
200 and 201, but these did not reduce susceptibility to inhibitory
antibodies. Apart from residue 197, the HB3 hybrid allele only
differed from W2Mef at residue 200. Together, these findings
suggest that changes at residue 197 most strongly influence
antibody escape with anti-W2Mef. Of note, the hybrid line
expressing HB3 C1-L had inhibition by anti-HB3 antibodies 30%
higher that the W2–W2 control (P = 0.0124, Figure 6D), further
suggesting the importance of this region as a target of inhibitory
antibodies. There was very little inhibition by anti-FVO and anti-
3D7 antibodies across the five transgenic lines (Figure 6D).
Discussion
Our findings provide important new knowledge on AMA1-
based vaccines and understanding immune escape. The diversity
of AMA1 inhibitory epitopes is lower than expected from sequence
analyses, with substantial antigenic overlap between different
alleles. Our results support the concept that, when combined,
antibodies raised against four different alleles increases median
growth inhibition across all isolates. As such, a vaccine containing
four AMA1 alleles may cover allelic-diversity, provided the right
alleles are selected. Additionally, we developed novel tools and
approaches to dissect the importance of specific polymorphic
epitopes and quantified the importance of polymorphisms in the
C1-L region.
The premise that immune selection drives the evolution of
AMA1 diversity suggests that an AMA1 vaccine must encompass
this diversity to be broadly cross-protective. Recent studies have
attempted to estimate global AMA1 sequence diversity and group
AMA1 haplotypes into clusters of related sequences [18,19] [17],
but how this sequence diversity relates to antigenic diversity has
been unknown. The results of the present study suggest that
antigenic diversity of inhibitory epitopes may be lower than
predicted by sequence analyses since a mixture of antibodies to
Figure 3. Relationship between sequence polymorphisms and growth inhibition by antibodies. Graphs show regression analysis of
normalised percent growth inhibition and AMA1 amino acid (aa) sequence identity. For each antibody, the percent growth inhibition against isolates
are plotted against the sequence identity (as a percentage; X axis) relative to the AMA1 allele used to generated the anti-allele antibody tested. This
was done for sequences corresponding to the ectodomain (aa 25–546), Domain 1 (aa 25–320), Domain 2 (aa 321–442), Domain 3 (aa 443–546) or C1-L
region (aa 196–207). The relationship between AMA1 sequence similarity and growth inhibition was analysed by linear regression. R2 and P values are
displayed in the top left of each graph. The solid line represents the line of best fit for each scatter plot, and dashed lines represent the standard
deviation. Growth inhibition for each isolate by AMA1 antibodies was normalised relative to the inhibition of the parental parasite isolate (e.g.:
antibody inhibition of the HB3 isolate by anti-HB3 antibodies was defined as 100%).
doi:10.1371/journal.pone.0051023.g003
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four alleles was sufficient to inhibit a diverse panel of P. falciparum
isolates. Our findings suggest that sequence differences are not
a strong predictor of antigenic differences or the cross-inhibitory
activity of anti-allele antibodies. Correlations between the level of
sequence polymorphism and cross-inhibitory activity against
different isolates were modest and inconsistent across the four
anti-allele antibodies, when the whole ectodomain, separate
domains or discrete regions were considered. Not all polymorph-
isms mediate the same level of immune escape (Figures 5 and 6)
[44] [22], and not all polymorphism in AMA1 may be relevant to
antibody inhibitory activity, which is not accounted for in
sequenced-based analyses. Our findings suggest that while large
differences in AMA1 sequence are required for vaccine escape, the
value of sequence-based analysis for predicting escape from
inhibitory antibodies may be limited.
By generating parasites with modified AMA1 alleles, we
demonstrated that while the polymorphic C1-L epitope is
a significant target of some inhibitory antibodies in GIA, these
antibodies only constitute a minor proportion of the total
inhibitory antibody repertoire induced by immunisation.
W2Mef-AMA1 antibodies targeting the C1-L epitope accounted
for 38% of total inhibition, and C1-L also appeared important for
HB3. In contrast, C1-L polymorphisms did not have a major effect
with the 3D7 allele. This conflicts with previous studies using
modified recombinant proteins of 3D7-AMA1 [18], which may
differ in the way epitopes are presented compared to native
proteins on merozoites. The advantage of using transgenic
parasites to dissect specific epitopes or polymorphisms is that
AMA1 is presented in its native conformation and context, before
and during erythrocyte invasion. The recent phase 2b vaccine trial
of 3D7-AMA1 in Mali reported protection against parasites
carrying the 3D7 C1 epitope (defined by residues 196, 197, 199,
200, 201, 204, 206, 207) [15]. This indicates that all 8
polymorphic residues in the C1 region may be responsible for
modulating strain-specific antibody binding. As the 3D7 and FVO
C1-L exchanged in the 3F3 hybrid differed by only 5 residues (aa
196, 197, 200, 204 & 206), it is possible that we did not introduce
a sufficiently diversified C1-L to alter inhibitory antibody binding.
By testing parasites with different mutations in the C1-L region,
our results support the importance of polymorphisms at position
197 for immune escape with the W2Mef allele, but not with the
3D7 allele. The importance of specific polymorphic epitopes and
residues may differ between alleles, and the importance of specific
epitopes as antibody targets may also differ between naturally-
acquired and vaccine-induced responses and between different
individuals within a population. Our studies provide an important
proof-of-principle for using this novel approach to determine the
significance of specific polymorphisms and the transgenic parasite
Figure 4. Transgenic and wild type parasite lines expressing the same AMA1 alleles share the same phenotype. A. Plasmid design and
integration. Codon optimised W2Mef, 3D7 and FVO AMA1 alleles were transfected into W2Mef parental parasites. The single-crossover event for
allelic replacement of the wild type (WT) AMA1 is illustrated. B. Southern blot. Genomic DNA from parental W2Mef and transfected parasites was
digested with restriction enzymes as indicated and hybridised with an AMA1 probe. Expected sizes for WT, non-integrated plasmid and integrated
3F3-AMA1 are shown in kilobases (kb). C. Differential growth inhibition of wild type and transgenic parasite lines by anti-W2Mef#1 antibodies tested
at a final dilution of 1:10. * indicate a significant difference in inhibition when compared to the W2Mef reference line, P,0.05 by t-test. D, E, F
Phenotypic comparisons between the parental and transgenic parasites for W2Mef, 3D7 and FVO alleles of AMA1. Each figures shows the expression
of W2Mef, 3D7 and FVO AMA1 in transgenic parasites compared to the corresponding parental parasite isolate by western blot and growth inhibition
of transgenic parasites compared to the corresponding parental parasite isolate with AMA1 allele-specific antibodies.
doi:10.1371/journal.pone.0051023.g004
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lines we have generated could be valuable to dissect vaccine-
induced responses and assess vaccine-escape in future clinical
trials.
Prior studies on the inhibitory activity of antibodies induced by
immunization with a mixture of three or four different AMA1
alleles also suggest that broadly inhibitory antibodies are
generated, although the number of different isolates tested in
these studies has been very limited [45–46]. These studies also
suggested that immunization with a multi-allele mixture enhances
the induction of cross-reactive antibodies, which would be
beneficial in covering global diversity in AMA1 [45]. Alternative
approaches to overcome antigenic diversity of AMA1 have been
explored recently. Alanine-mutagenesis of polymorphic C1
residues was used in attempt to reduce the antibody response to
highly polymorphic epitopes of AMA1. However, this approach
failed to broaden inhibitory-antibody responses towards common
epitopes and had a negative effect of reducing the overall
inhibitory activity of vaccine-induced antibodies [47]. Another
approach being developed in an effort to overcome antigenic
diversity is the generation of synthetic AMA1 sequences (DiCo)
that aim to represent the majority of AMA1 diversity in three
synthetic alleles, giving equal weighting to all polymorphic sites
[48–49]. Initial reports suggest that this may generate broad
growth-inhibitory activity; however, to date, only a small number
of different isolates has been tested for inhibition by anti-DiCo
antibodies. Our results suggest that the antigenic diversity of
AMA1 is not extensive; therefore, a mixture of DiCo antigens, or
of naturally-occurring alleles, might be sufficient to overcome
antigenic diversity in AMA1. Interestingly, antibodies induced by
immunization with a mixture of three DiCo antigens appeared to
have lower inhibitory activity than antibodies induced by
immunization with a mixture of three naturally-occurring alleles
[49].
Our findings support the concept and feasibility of developing
a multi-allele AMA1 vaccine for malaria and suggest that the
promising strain-specific protective effects shown in the recent
phase 2b trial of a mono-allelic vaccine can be broadened using
a multi-allele approach. While the four AMA1 alleles used in this
study were useful for establishing this concept, further studies are
needed to determine the optimum formulation of specific alleles
required in a multi-allele vaccine that maximizes coverage in
different populations, and to determine concentrations of in-
hibitory AMA1 antibodies required for protective immunity. The
novel approaches developed in this study using transgenic parasites
Figure 5. The importance of polymorphisms in the C1-L region of 3D7 for vaccine escape. A. Plasmid design and integration. The C1-L of
3D7 and FVO AMA1 differ by 5 amino acid (aa) residues located at positions 196, 197, 200, 204 and 206. The hybrid 3F3 AMA1 (3D7 allele with the
FVO C1-L sequence) was transfected into W2Mef parental parasites. The single-crossover event for allelic replacement of the wild type (WT) AMA1
with 3F3 is illustrated. B. Southern blot. Genomic DNA from parental W2Mef and transfected parasites was digested with restriction enzymes as
indicated and hybridised with an AMA1 probe. Expected sizes for WT, non-integrated plasmid and integrated 3F3-AMA1 are shown in kilobases (kb).
C. Phenotypic analysis of transgenic parasites expressing the 3F3-AMA1 hybrid. Transgenic W2Mef parasites expressing 3D7-AMA1 (W2-3D7), FVO-
AMA1 (W2-FVO) or the hybrid 3F3-AMA1 (W2-3F3) were tested for their susceptibility to growth inhibition with the R1 peptide (final concentration
100 mg/ml) or the monoclonal antibody 1F9 (final concentration 0.2 mg/ml). D. Differential growth inhibition of transgenic parasite lines by
polyclonal rabbit antibodies to AMA1; anti-W2Mef #1 and anti-FVO#2 rabbit sera were tested at a final dilution of 1:10, all other antibodies listed
were tested at a final concentration of 2 mg/ml IgG. Columns represent the mean parasite growth inhibition achieved in two separate assays tested
in triplicate wells. * indicate a significant difference in inhibition when compared to the W2-3D7 reference line, P,0.05 by t-test.
doi:10.1371/journal.pone.0051023.g005
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could be valuable to define the importance of specific polymorphic
residues and regions for vaccine escape, thereby aiding the
selection of specific alleles for vaccine inclusion.
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